Clinical Trial Details
— Status: Withdrawn
Administrative data
| NCT number |
NCT03479151 |
| Other study ID # |
17/LO/1689 CCR 4733 |
| Secondary ID |
|
| Status |
Withdrawn |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
March 16, 2018 |
| Est. completion date |
January 7, 2021 |
Study information
| Verified date |
October 2021 |
| Source |
Institute of Cancer Research, United Kingdom |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The primary objective of this study is to determine whether intra- and post-procedural MR
changes are indicative of reduction in pain symptom scores. The trial will recruit a cohort
of patients with painful bone metastases, who wish to consider MRgHIFU treatment. These
patients will be identified in conjunction with the pain and palliative care teams, as well
as clinical and medical oncologists. Patients will undergo MRgHIFU treatment using scanning
and treatment planning methods that have been established in the patients treated within the
multi-centre study. The treatment response rate for the cohort will be recorded. Intra- and
post-procedural imaging metrics will be evaluated for their ability to detect tissue changes,
which may be indicative of response. Patients will be followed-up for up to 90 days after
treatment, and will attend for repeat imaging and pain review at days 30, 60 and 90 after
treatment. Any changes in imaging metrics will be compared between responders and
non-responders.
Description:
The primary aim of this study is to investigate whether the ablated tissue volume indicated
by immediate post-treatment Gd-T1W imaging is indicative of reduction in pain scores
(response) 30 days after treatment.
The secondary aims of this study are:
- To record the proportion of patients responding to MRgHIFU treatment at Days 7, 14, 30,
60 and 90 after treatment
- To investigate whether intra-procedural PRFS metrics (thermal dose volume, temperature)
are indicative of subsequent treatment response
- To investigate whether intra- or post-procedural changes in ADC or T2 are indicative of
subsequent treatment response
- To record adverse events arising as a result of MRgHIFU treatment
- To evaluate the effect of MRgHIFU treatment on patients' quality of life
- To record the time to pain progression and the duration of pain response for patients in
this cohort
- To estimate the costs of MRgHIFU treatment
This is an exploratory study, which will recruit n=15 patients into one single cohort.
Enrolment of the target population for the study is expected to take approximately 2 years.
Patients will be eligible for the study if they wish to consider MRgHIFU treatment for pain
palliation of a region of bony metastatic disease that is accessible to the MRgHIFU device.
After providing their written informed consent to participate in the study, patients'
suitability for treatment will be determined by a combined assessment of clinical review by a
pain specialist, and an MR screening investigation to establish lesion targetability.
Baseline clinical and imaging metrics will be recorded. Patients who fulfill all inclusion
criteria, have none of the exclusion criteria, and who give informed consent, will be
scheduled for MRgHIFU treatment to the target lesion. Treatment will be delivered under
sedation on a day-case basis, according to protocols already established in our prior study.
During treatment delivery, the investigators will assess imaging metrics of tissue change,
which may be indicative of subsequent treatment response. Treatment would be expected to take
approximately 1-2 hours, and after an observation period of approximately 2-4 hours, the
patient will be discharged. Before discharge, follow-up instructions will be given to the
patient. Patients' clinical and imaging responses to treatment will then be assessed at
follow-up appointments up to 3 months after treatment.
